Aucun résultat
Dr. Stephanie M. Wong’s laboratory explores clinical outcomes and prevention strategies for women at increased breast cancer risk. Her research focuses primarily on patients with inherited susceptibility due to germline pathogenic variants in BRCA1/2, PALB2, ATM, CHEK2 and other genes, as well as those with a history of atypical breast biopsies or a personal history of chest wall radiation therapy in adolescence and young adulthood. For these high risk groups, her research explores uptake and decision making around endocrine prevention and risk reducing mastectomy. She is also involved in initiatives around mainstream genetic testing for patients with newly diagnosed breast cancer.
Dr. Stephanie M. Wong’s research focusses on surgical decision making and prevention strategies in high-penetrance germline pathogenic variant carriers, including in BRCA1/2, PALB2, CDH1, TP53 and PTEN genes.
Her specific areas of research include:
Wong SM, Foulkes WD. Med J Aust 2023 Apr 4. doi: 10.5694/mja2.51916.
Wong SM, Ferroum A, Apostolova C, Alhassan B, Prakash I, Basik M, Boileau JF, Meterissian, S, Wong N, Foulkes WD. Ann Surg Onc, 2022 Oct; 29(11): 6660-68.
Eisenberg E, Weiss A, Ajjamada L, Prakash I, Skamene S, Boileau JF, Pollak M, Basik M, Wong SM. Ann Surg Onc, 2022 Oct;29(11): 6673-80.
Wong SM, Ajjamada L, Weiss A, Prakash I, Skamene S, Boileau JF, Pollak M, Basik M. Cancer Apr 2022; 128(7):1365-1372.
Wong SM, Stout NK, Punglia R, Prakash I, Sagara Y, Golshan M. Cancer 2017, Jul 15;123(14):2609-17.
